MicroRNAs : short non-coding players in cancer chemoresistance by S. Donzelli et al.
REVIEW Open Access
MicroRNAs: short non-coding players in cancer
chemoresistance
Sara Donzelli1, Federica Mori2, Francesca Biagioni1, Teresa Bellissimo1, Claudio Pulito2, Paola Muti3,
Sabrina Strano2,3 and Giovanni Blandino1,4*
Abstract
Chemoresistance is one of the main problems in the therapy of cancer. There are a number of different molecular
mechanisms through which a cancer cell acquires resistance to a specific treatment, such as alterations in drug
uptake, drug metabolism and drug targets. There are several lines of evidence showing that miRNAs are involved in
drug sensitivity of cancer cells in different tumor types and by different treatments. In this review, we provide an
overview of the more recent and significant findings on the role of miRNAs in cancer cell drug resistance. In
particular, we focus on specific miRNA mechanisms of action that in various steps lead from drug cell sensitivity to
drug cell resistance. We also provide evidence on how miRNA profiling may unveil relevant predictive biomarkers
for therapy outcomes.
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Introduction
Cancer is one of the leading causes of death worldwide
where significant effort in searching for more effective
therapies are relentlessly taking place. Chemotherapy,
in synergy with radiotherapy and surgery, are the ap-
proaches commonly used for cancer treatment.
The main problem in cancer therapy is the frequent
occurrence of resistance to different chemotherapeutic
drugs that allows cancer cells to proliferate uncon-
trollably and to become more aggressive with a greater
ability to metastasize to other organs.
Tumors can display either an intrinsic chemoresis-
tance being originally insensitive to the treatment, or an
acquired chemoresistance, being responsive at the begin-
ning and then later becoming refractory to the cure [1].
In both cases the result is an inefficient intervention
with consequent worsening of the disease.
Different mechanisms of cell chemoresistance have
been described in the last few decades and can be
roughly categorised in three main groups: 1) impairment
in drug concentration due to either decreasing in drug
influx or increasing in drug efflux; 2) alteration in drug-
target connection; and 3) modification in cell-cycle and
checkpoint mediators. An important feature in the field
of chemoresistance is that a cancer cell may not only
possibly be or become resistant to one drug, but also to
different drugs. This latter phenomenon is known as
multidrug resistance (MDR).
It has become vital to find the underlying molecular
mechanisms involved in the drug resistance process to
identify its determinants and regulators with the aim to
discover specific new compounds able to interfere with
that process.
Recent and numerous studies have pointed out the
importance of microRNAs (miRNAs) in regulating many
biological processes among which the regulation of
tumor cell sensitivity to drugs.
MiRNAs are a family of small non-coding RNAs of
20–25 nucleotide length that are evolutionarily con-
served across species and regulate gene expression at the
post-transcriptional level [2,3].
MiRNA biogenesis occurs in two different steps (Figure 1).
In the nucleus, RNA Polymerase II transcribes miRNA
genes in 170 bp primary transcripts (pri-miRNA) that
contain both a 5’cap and a poly (A) tail and fold into a
hairpin-shaped structure [4]. The Nuclear RNase III
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Drosha in cooperation with DGCR8 cofactor recognize
and cleave these precursor molecules into a 70 nucleotide
pre-miRNA [5]. Pre-miRNA is then exported in the cyto-
plasm through a process involving Exportin5 protein that
is able to recognize a protruding tail of 2–3 nucleotides at
3’-end of the hairpin and promotes translocation into
the cytoplasm [6,7]. In the cytoplasm the RNAse Dicer
binds and processes pre-miRNA in the transitory 22 bp
miRNA-3p/miRNA-5p duplex. Within this process TRBP
(TAR RNA-binding protein) and Ago2 assist Dicer as
part of the RISC Loading Complex [8,9]. One strand of
this RNA duplex, the mature miRNA, enters into the
miRNA–induced silencing complex (miRISC). Once in
the miRISC, partial pairing between a miRNA and the
3’UTR of target mRNA results either in the repression of
protein translation or, in case of complete pairing, in
mRNA degradation [10].
MiRNAs regulate more than 50% of human transcrip-
tome and thereby control the global activity of the cell. In-
deed, miRNAs affect most cellular processes such as cell
proliferation, differentiation, apoptosis, stress response,
metabolism and angiogenesis. Therefore, it is not sur-
prising that aberrant expression of miRNAs can be asso-
ciated to human pathologies, including cancer [11].
Due to the small size and stability of miRNAs mole-
cules they can be transferred from one cell to another
one in different ways. Different studies have shown the
transfer of miRNAs among cancer cells and between
breast cancer cells and bone marrow stroma. This oc-
curs through the gap junctions [12]. There is also
evidence showing exosome-mediated directed transfer
of specific miRNAs between cells. Montecalvo et al., re-
ported that dendritic cells (DCs) secrete exosomes
loaded with distinct sets of miRNAs that are related to
the status of DC activation [13].
The role of miRNAs in the control of cancer cell
chemoresistance has been confirmed by different studies
highlighting how the deregulation of miRNAs expression
can lead to a chemoresistant phenotype in different tumor
types [14]. Therefore, miRNA activity could impinge on
drug effects by modulating the expression of genes in-
volved in the apoptotic response, in the DNA repair or in
the control of cell cycle. MiRNA can also be under the
control of different tumor suppressor genes or oncogenes,
thus they might consequently be the intermediate effec-
tors of a specific response to treatments. MiRNAs may
also modulate the expression of genes involved in drug
transport or metabolism. There is now increasing
Figure 1 The biogenesis of miRNAs. RNA polymerase II transcribes miRNA gene, generating a long primary transcript (pri miRNA). Drosha-mediated
cleavage of pri-miRNA leads to the formation of a hairpin molecule, the pre-microRNA that is exported to the cytoplasm by the complex exportin-5/
RAN-GTP. In the cytoplasm, Dicer cleaves the pre-miRNA and produces a ~22-nt RNA duplex. The functional strand of the duplex is incorporated into a
multiple-protein nuclease complex, the RNA-induced silencing complex (RISC), which regulates protein expression.
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evidence that miRNAs can be predictor markers of che-
motherapeutic response.
Below, we describe most of the different aspects of
miRNA involvement in anticancer treatment response
(see Table 1).
miRNAs as modulators of drug effects
Modulation in DNA-repair pathways
Chemotherapeutic drugs act in tumor cells affecting dif-
ferent cellular functions and causing different cellular re-
sponses. DNA damage response is the first reaction to
genotoxic injury. Beyond the importance of this machin-
ery for the integrity of the cells, alterations in the compo-
nents of the DNA repair machinery is associated with
chemoresistance. This is specifically evident in the case of
platinum agents and alkylating compounds [15]. There are
three fundamental pathways to repair damaged DNA:
Nuclear excision repair (NER), Base excision repair (BER)
and DNA mismatch repair (MMR) and all of them are, at
different levels, involved in the chemoresistance.
Several recent studies have demonstrated how onco-
genic miRNAs may interfere with DNA-repair pathways
allowing cells to resist drugs that initially were effective
against them. One example of this resistance is miR-155
which significantly down-regulates the mismatch repair
recognition protein complex MSH2-MSH6 and MLH1-
PMS2 [16]. Also miR-21 has been shown to contribute to
chemoresistance by interfering with the DNA-repair sys-
tem. Valeri and collaborators demonstrated that miR-21
targets MSH2 and MSH6 proteins determining an in-
creased resistance to 5-fluorouracil treatment in colorectal
cancer [17].
One of the initial signs of DNA damage is the phospho-
rylation of the histone H2A variant H2AX (γ-H2AX) by
the ATM/ATR signalling pathway. Wang and colleagues
identified miR-138 as a direct inhibitor of H2AX expres-
sion [18]. The authors initially performed a cell-based
miRNA library screening, using IR-induced γH2AX foci
formation as readout. From this experiment they obtained
a list of miRNAs that regulated γH2AX foci formation.
Then they focused their attention on miR-138, which had
the most robust effect on γH2AX transcript. By further in-
vestigations they also demonstrated that overexpression of
miR-138 sensitized tumor cells to DNA damaging agents
such as cisplatin and camptothecin.
ATM activation represents an early and important
event for DNA repair upon DNA double strand breaks.
Wu and colleagues identified mir-18a which directly
Table 1 miRNAs involved in chemoresistance
Pathway microRNA Target
gene
Effect on chemoresistance Cancer type Reference
APOPTOSIS miR-125b p53 Bak Resistance to doxorubicin,
vincristin, etoposide, mafosfamide
Ewing sarcoma/pri itive neuroectodermal tumor [24]
miR-34a SIRT1 Sensitivity to camptothecin Prostate cancer [27]
miR-128-2 E2F5 Resistance to cisplatin, doxorubicin,
5-fluorouracile
Lung cancer [39]
miR-223 STMN-1 Sensitivity to cisplatin,
5-fluorouracil
Breast cancer, colon cancer [40]
miR-21, miR-221,
miR-214
PTEN Resistance to gemcitabine,
cisplatin, gefitinib
Malignant human cholangiocytes, gastric cancer
osteosarcoma, ovarian cancer, lung cancer
[42-48]
DNA REPAIR miR-155, miR-21 MSH2,
MSH6
Resistance to 5‐fluorouracil Colorectal cancer [16,17]
miR-138 H2AX Sensitivity to cisplatin,
5-fluorouracil
Osteosarcoma [18]
miR-18a ATM Sensitivity to etoposide Colorectal cancer [19]
miR-182 BRAC1 Sensitivity to PARP1 inhibitor Breast cancer [21]
MDR miR-298, miR-27a,
miR‐331‐5p
P-gp Sensitivity to doxorubicin Breast cancer, leukaemia [66,69]
miR-19a/b, PTEN Resistance to cisplatin, doxorubicin,
5-fluorouracil
Gastric cancer [67]
miR-451 - Resistance to vinblastin Ovarian cancer [68]
miR-326 MRP1 Sensitivity to VP-16 Breast cancer [70]
miR-520 h, miR-519c,
miR‐328
BCRP Sensitivity to mitoxantrone Hematopoietic stem cell, lung cancer,
breast cancer, colon cancer
[71-73]
DRUG
METABOLISM
miR-27b CYP1B1 Induction Breast cancer [74]
miR-148a CYP34A Induction Liver cancer [75]
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binds to ATM 3’UTR inducing increased sensitivity of
colorectal cancer cells to etoposide [19].
Moreover, it was recently demonstrated that in triple
negative breast cancers, miR-181 a/b are negative regu-
lators of ATM expression and that these two miRNAs
sensitize cancer cells to poly-ADP-ribose-polymerase 1
(PARP1) treatments [20].
Moskwa and collaborators showed that miR-182 expres-
sion impacts on BRCA1 protein expression in different
breast cancer cell lines, determining its downregulation
and a consequent increase in sensitivity to PARP1 inhibi-
tor either in cultured cells or in xenograft models [21].
Alterations in apoptotic pathways
After DNA damage induced by anticancer drugs, injured
cells can react in two ways: either by cell cycle arrest
and damage repair or, if the problem is far too extensive
to repair, cell death and apoptosis.
The final goal of cancer treatment is the death of the
transformed cells. Defects in the apoptotic machinery
have been described to play an important role in drug
resistance [22].
Some miRNAs involved in chemoresistance act at spe-
cific steps in this pathway influencing the balance towards
cell survival despite cell death.
The tumor suppressor protein p53 is a central player
in the regulation of cell cycle arrest and cell death, and
it is activated in response to different chemotherapeutic
drugs [23].
Recently, Iida and colleagues demonstrated that miR-
125b induces chemoresistance to doxorubicine, vincristine,
etoposide and mafosfamide in Ewing sarcoma/primitive
neuroectodermal tumor (EWS) by suppressing p53-de-
pendent apoptosis [24]. In particular, they observed higher
levels of miR-125b in doxorubicin-resistant EWS cells
(VH-64/ADR) by comparing miR-125b expression in the
parental VH-64 cells; when miR-125b was stably down-
regulated, an increase in caspase 3 cleavage, along with
enhanced cell death upon doxorubicin treatment were evi-
denced. They also observed that p53 and Bak genes are
among the putative miR-125b target mRNAs, thereby
showing that miR-125b-mediateted chemoresistance is
due to its ability to target p53 and Bak expression.
Likewise, miR-140 has been shown to interfere with
p53-mediated apoptosis. Song and colleagues demon-
strated that miR-140 promotes chemoresistance only in
a wild type p53 cellular context. The chemoresistant
effect of miR-140 is due to its ability in reducing cell
proliferation and in inducing cell cycle arrest protecting
cells from chemotherapy-induced damage. This occurred
mainly by the reduction of HDAC4 protein expression
only in p53 wild type cells.
p53 protein itself has been shown to modulate miRNAs
expression and to induce cell cycle arrest and apoptosis:
miR-34a is one of p53 effector genes [25]. Fujita and col-
leagues analyzed miR-34a expression in different prostate
cancer cell lines with different p53 protein status (null,
mutated or wild-type) observing a strong linear correl-
ation between its expression and p53 wild-type expression
[26]. They also demonstrated that ectopic expression of
miR-34a in p53-null or p53-mutated prostate cancer cells
restores chemosensitivity to camptothecin by suppression
of SIRT1 and consequent induction of cell cycle arrest
and apoptosis.
miR-122 was demonstrated to be a positive regulator
of p53 protein stability able to contribute to chemosensi-
tivity. One of the miR-122 target genes is cyclin G1, a
well known negative regulator of p53 protein stability
[27,28]. Moreover, it has been shown that miR-122 over-
expression in HCC cells restores sensitivity to doxorubi-
cin treatment [27].
TP53 gene mutations are the most frequent event in hu-
man cancers. They are mainly missense mutations in the
exons encoding for p53 DNA-binding domain [29,30].
The resulting proteins are full-length p53 proteins unable
to bind DNA and to transactivate genes eliciting anti-
tumoral activities [31]. Some mutant forms of p53 protein
not only lose the wild-type activity but also acquire new
functions that promote tumorigenesis [32-34]. Mutant
p53 proteins can exert this gain of function activity
through different molecular mechanisms. Among them,
the most known are those implying both the transcrip-
tional activation of oncogenic target genes through the
physical interaction with other transcription factors, and
the binding and sequestering of tumor suppressor pro-
teins, such as p73 and p63, and the consequent im-
pairment of their tumor suppressor activities [35-38]. In
addition to this evidence, we have also observed a new
mechanism by which mutant p53 exerts its gain of func-
tion activity, in particular chemoresistance: the regulation
of miRNAs expression [39,40]. Donzelli et al., originally
identified miR-128-2 as a direct transcriptional target in-
duced by mutant p53His175 protein, a well known mutant
form of p53 that exerts gain of function activity. miR-128-2
overexpression determined an increase in chemoresistance
to different anticancer drugs (cisplatin, doxorubicin and
5-fluorouracil). miR-128-2 targets the transcriptional re-
pressor E2F5 which in turn resulted in the accumulation of
cytoplasmic p21 protein, a feature that is frequently asso-
ciated with the anti-apoptotic effect of p21. Indeed, lung
cancer cells overexpressing miR-128-2 exhibit an increased
chemoresistance to commonly anticancer treatments [40].
Masciarelli et al., showed that mutant p53His175 pro-
tein is able to inhibit miR-223 expression at the tran-
scriptional level both in breast and colon cancer cell
lines. This happened through the formation of a protein
complex involving mutant p53 proteins and the tran-
scriptional repressor ZEB1 on the miR-223 promoter.
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This transcriptional inhibition determined an increase in
cell resistance to cisplatin and 5-fluorouracil treatments
through at least in part, the up-regulated expression of
miR-223 target STMN-1, a well known oncoprotein that
is over-expressed in different human cancers, whose re-
gulation is essential for cell cycle progression. Indeed,
STMN-1 silencing by miR-223 overexpression induced an
increase in cdk1 phosphorylation on residues Thr14/
Tyr15, a modification that inhibits cdk1 activity, blocking
the entrance into the M phase [39].
In summary, these two studies identified two miRNAs
that contrastingly contribute to mutant p53-dependent
chemoresistance.
More recently, Ganci et al. contributed significantly to
correlate p53 mutations, selective expression of miRNAs
and clinical output of head and neck cancer patients [41].
In particular, miRNA expression profiling of 121 head and
neck squamous cell carcinoma (HNSCC) samples and 66
normal counterparts, allowed the identification of a group
of 12 miRNAs whose expression correlates with short re-
currence-free survival and a group of 4 miRNAs that
correlates with worse cancer-specific survival of patients
carrying p53 mutations.
PTEN is another important tumor suppressor gene cor-
related to chemotherapeutic response. In fact, its inactiva-
tion is often involed in drug resistance. Different miRNAs
have been shown to regulate tumor cell chemoresistance
by targeting PTEN. miR-21has been reported to regulate
PTEN expression and the phosphorylation of its down-
stream kinase Akt, determining an increased sensitivity to
gemcitabine in malignant human cholangiocytes and to
cisplatin in gastric cancer [42-45]. Recently, Zhao et al.
have identified miR-221 as a mediator of osteosarcoma
cells resistance to cisplatin by demonstrating its ability
to downregulate PTEN expression. They also observed a
strong inverse correlation between miR-221 expression
and PTEN protein levels in osteosarcoma tissues [46]. In
two different studies miR-214 has been shown to mediate
resistance to cisplatin of ovarian cell cancer and to
gefitinib of non-small cell lung cancer EGFR mutated cell
lines through the targeting of PTEN expression [47,48].
Liang and colleagues have shown the involvement of
miR-19 in the regulation of multidrug resistance (MDR)
of breast cancer cells through PTEN inhibition [49].
In contrast, Li and colleagues identified miR-22, a
tumor suppressor miRNA, as a positive regulator of
PTEN. In colon cancer cells carrying mutant p53 protein
miR-22 enhanced cell sensitivity to paclitaxel treatments
by promoting PTEN expression and the consequent in-
hibition of Akt phosphorylation [50].
Recently, Rao and colleagues identified miR-17-92 clus-
ter as a mediator of chemoresitance in mantle cell lym-
phoma [51]. miR-17-92 cluster is able to activate PI3K/
Akt pathway by targeting two different proteins, both of
them involved in the inhibition of this pathway: PTEN
and PHLPP2, a member of PP2A-type phosphatases
family. PTEN acts by removing the activating lipid second
messenger, while PHLPP2 acts by promoting the dephos-
phorylation of activated AKT. Moreover, the authors iden-
tified another miR-17-92 cluster target protein: BIM. It is
one of the most potent pro-apoptotic BH3-only proteins,
which binds to all pro-survival BCL2 family members
with high affinity, thereby releasing BAX and BAK pro-
teins, the critical downstream effectors of the BCL2-
regulated pathway of apoptosis. miR-494 overexpression
determined a reduction of BIM protein level and a con-
sequent increase in TRAIL-resistance in non small cell
lung cancer [52].
Yan and colleagues showed that in pancreatic cancer
cells miR-17-5p induced an increase in chemoresistance
to gemcitabine by targeting BIM 3’UTR.
BIM has also been shown to be a target of miR-10b in
colorectal cancer cells. miR-10b-mediated downregula-
tion of BIM expression determined chemoresistance to
5–fluorouracil [53].
Two recent lines of evidence revealed also Bcl2l, an anti-
apoptotic protein of Bcl2 family, to be under miRNAs con-
trol. In particular, Wang and colleagues identified miR-214
as the mediator of increased chemosensitivity to cisplatin
in cervical cancer cells due to its ability to directly counter-
act Bcl2l expression, determining an increased expression
of Bax, caspase-9, caspase-8 and caspase-3 [54]. Qu and
collaborators demonstrated that miR-195 was downregu-
lated in doxorubicin-resistant colon cancer cells and that
its suppression in parental cells caused a significant reduc-
tion of doxorubicin induced apoptosis due to its ability to
downregulate Bcl2l protein expression. They also validated
this evidence in vivo demonstrating a marked inverse
correlation between miR-195 and Bcl2l expressions in
doxorubicin-resistant and sensitive colon cancer tissues
[55]. MiR-204 has recently been shown to be involved in
cells chemo-sensitivity to anticancer drugs due to its in-
hibitory effect on Bcl2 expression. In particular, Ryan and
colleagues demonstrated miR-204’s role in increased neu-
roblastoma cell sensitivity to cisplatin treatment [56].
Sacconi and collaborators profiled miRNAs expression in
gastric cancer tissue by comparing the tumoral and the
matched peritumoral samples and they identified miR-204
downregulation to be a prognostic factor for gastric cancer
[56,57]. MiR-204 ectopic expression significantly poten-
tiated the apoptotic effects induced by either oxaliplatin or
5-fluorouracil on gastric cancer cell lines by reducing the
expression of Bcl2 protein.
Both intrinsic and extrinsic apoptotic pathways result in
the activation of caspase-3, the main apoptotic effector. It
has also been demonstrated that let-7a exogenous expres-
sion in human squamous carcinoma and hepatocellular
carcinoma cells increased the resistance to different
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therapeutic drugs, such as interferon-gamma, doxorubicin
and paclitaxel by targeting caspase-3 [58]. More recently,
Quintavalle and colleagues identified miR-30 b/c and
miR-21 to be upregulated in TRAIL-resistant cells [59]. By
further in vitro investigations they identified the molecular
mechanism by which miR-30b/c and miR-21 determined
a TRAIL-resistant phenotype. MiR-21 has been shown to
inhibit caspase-3 expression by directly binding to its
mRNA 3’UTR, while miR-30 has been demonstrated to
bind the 3’UTR of TAp63, inducing its translational re-
pression, that in turn determining the downregulation of
different genes involved in apotosis-control, such as
TRAIL receptors genes.
Miller and colleagues showed that miR-221 and miR-
222 contribute to tamoxifen resistance of breast cancer
cells by targeting p27 kip [60]. They also observed a higher
expression of miR-221 and miR-222 in HER2/neu-positive
primary human breast cancer tissues (known to be re-
sistant to endocrine therapy) compared with HER2/neu-
negative tissue samples.
miRNAs in the control of drug uptake
The balance between the entering and exiting of a drug is
fundamental within the cancer cell. Drugs enter in a cell
in different ways, from diffusion to endocytosis or through
the use of a protein functioning as a transporter. Decrea-
sing drug concentration could be affected by a mutation
that modify or eliminate the functional activity of cell sur-
face molecules. For example, cells resistant to metotrexate
have commonly mutated folate binding proteins [61].
Alterations in drug efflux were widely studied and con-
sidered one of the primary causes of multidrug resistance
(MDR) [62]. In particular, overexpression of ABC (ATP
binding cassette) super family of transporters by tumor
cells is closely linked to chemoresistance [63]. ABC trans-
porters are transmembrane proteins that through ATP
hydrolysis transport drugs outside of the cells against a
drug gradient. Three ABC proteins were mainly described
for most MDR in humans: P-glycoprotein (P-gp), MDR-
associated protein 1 (MRP1) and breast cancer resistance
protein (ABCG2) [64].
Different studies have shown that also the expression
MDR-related proteins is regulated by miRNAs in different
tumor types. Bao et al. observed a decreased expression of
miR-298 which paired with increased expression of P-gp
by comparing miRNAs expression between doxorubicin-
sensitive and -resistant breast cancer cells [65]. They
found that miR-298 directly bound to P-gp 3’UTR causing
its downregulation and consequent increase of breast can-
cer cell sensitivity to doxorubicin.
Recently, miR-19a/b have been implicated in multi-
drug resistance mechanism [66]. The expression of these
miRNAs was upregulated in a multidrug-resistant gastric
cancer cell lines and in turn determined increased P-gp
expression levels. This led to an accelerated drug efflux
through the modulation of PI3K/Akt pathway. MiR-451
and miR-27a have also been shown to be directly corre-
lated to P-gp overexpression in multidrug-resistant ovar-
ian and cervical cancer cell lines [67].
Liang and collaborators have identified miR-326 as an
inhibitor of multidrug resistant phenotype due to its
ability to directly downregulate MRP1 expression levels.
MiR-520 h in hematopoietic stem cells, miR-519c in
A459 lung cancer cell line and miR-328 in breast cancer
cells, have been shown to directly regulate the expres-
sion of BCRP [68-70].
miRNAs in the control of drug metabolism
Tumor cells can acquire resistance to a specific drug by
altering pathways involved in drug metabolism. The
super family of cytochrome p450 (CYP) enzymes play a
critical role in this important process. The expression of
some of its members is regulated by miRNAs. In par-
ticular, Tsuchiya and collaborators identified miR-27b as
a regulator of CYP1B1 protein expression. CYP1B1 is a
key member of the CYP family, is highly expressed in
tumor tissues and mediates the metabolism of a wide
range of drugs [71]. MiR-27b targeted CYP1B1 expres-
sion by binding its 3’UTR. Inverse correlation between
CYP1B1 and miR-27b expression levels in breast cancer
tissues has been evidenced; thereby suggesting that
CYP1B1 overexpression in tumor tissues could be a con-
sequence of miR-27b downregulation.
CYP3A4 is another key enzyme involved in drug me-
tabolism. It is mainly expressed in hepatic and intestinal
tissues. Takagi and colleagues identified miR-148a as
an indirect regulator of CYP3A4 expression levels [72].
They showed that mir-148a targeted the 3’UTR of pre-
game X receptor (PXR) that acts as a transcriptional
regulator of different genes among which CYP3A4. The
inhibitory effect of miR-148a on PXR expression resulted
in a decreased induction of CYP3A4 in liver cancer.
miRNAs as predictive biomarkers of chemotherapeutic
response
In light of the advances in miRNA detection techniques,
such as the development of microarrays, it is now pos-
sible to have a clear picture of the miRNA expression
profile for many types of cancer and to correlate it to a
particular type of anticancer agent response. All these
studies have been performed both in cancer cell lines
and in tumor tissues (see Table 2).
For instance, Kovalchuk and colleagues, found a signa-
ture of 137 deregulated miRNAs (63 upregulated and 75
downregulated) by comparing doxorubicine-resistant and
doxorubicine –sensitive breast cancer cell lines [73].
Another study carried out on a tamoxifene-resistant
breast cancer cell line, performed by Miller and collegues,
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led to the identification of a signature of 15 deregulated
miRNAs: 8 upregulated miRNAs (miR-221, miR-222,
miR-181, miR-375, miR-32, mir-171, miR-213, miR-203)
and 7 downregulated miRNAs (miR-342, miR-489, miR-
21, miR-24, miR-27, miR-23, miR-200) [60].
Boren and colleagues performed a miRNA microarray
analysis on 16 different ovarian cancer cell lines [74]. In
their study, they found 27 miRNAs highly associated
with response to one or more of the six chemoterapeutic
agents commonly used in ovarian cancer therapy (cis-
platin, doxorubicin, topotecan, paclitaxel, docetaxel, and
gemcitabine): 18 miRNAs showed increased expression
(miR-213, miR-181b, miR-181a, let 7e, miR-520f, miR-
21, miR-502, miR-514, miR-371, miR-99b, miR-518c-AS,
miR-515-5p, miR34b, miR-431, miR126, miR-23b, miR-
381, miR-340) and 9 miRNAs decreased expression
(miR-518c, miR-132, miR-330, miR-339, miR-142-5p,
miR-29c, miR-331, miR-185, miR-106a) with increasing
resistance to individual drugs. Seven out of 27 miRNAs
were associated with response to more than one drug
(miR-213, miR181a and miR 181b to doxorubicin and
gemcitabine; miR-99b and miR-514 to docetaxel and
paclitaxel; miR-518c-AS to docetaxel and topotecan;
miR-520f to doxorubicin and cisplatin). The authors also
performed a cross-analysis between the 27 miRNAs and
their predicted mRNA targets. They found 53 genes that
were previously shown to be predictive of chemotherapy
response.
In another miRNA profiling study, Sorrentino and col-
leagues further investigated the role of miRNAs in ovarian
cancer chemoresistance by analayzing the miRNA expres-
sion in a panel of paclitaxel- (A2780TAX, A2780TC1 and
A2780TC3) and cisplatin-resistant (A2780CIS) ovarian
cancer cells [75]. They described a signature of six miR-
NAs (let-7e, miR-30c, miR-125b, miR-130a and miR-335)
deregulated in all the resistant cell lines. In particular,
miR-30c, miR-130a and miR-335 were found to be down-
regulated in all the resistant cell lines, suggesting that they
play an important role in chemoresistance. Let-7e resulted
to be upregulated only in A2780TAX cells and to be
downregulated in the other cell lines. Conversely, miR-
125b expression was downegulated only in A2780TAX
and upregulated in the other cell lines. One of the most
important implications of these miRNAs in chemoresis-
tance was also confirmed by the validation of a target gene
miR-130a, M-CSF, whose downregulation is a wellknown
resistance factor in ovarian cancer.
More recently, Park and colleagues carried out a miRNA
profiling study by isolating the population of ALDH1(+)
cells, a potential cancer stem cell marker, in different ovar-
ian cancer cell lines (SKOV3, A2780, and OVCAR 3), che-
moresistant sublines (SKpac-12,-16,-17, A2780pac, and
A2780cis), and primary tumor cells (SCN-1–7) [76]. By
comparing the ALDH1(+) cells with the ALDH1(−) cells
they identified six miRNAs significantly overexpressed
(miR-424, miR-346, miR-503, miR-27a, miR-23b, and
miR-27b). Then, they investigated the impact of these six
ALDH1(+)-associated miRNAs on chemoresistance by
comparing their expression levels between chemoresistant
SKpac sublines and chemosensitive SKOV3 cell line. What
they found is higher expression levels of both six miRNAs
and ALDH1 protein in SKpac sublines. They validated
these results in ovarian cancer samples by finding greater
expression levels of miR-23b, mir-27b, miR-424 in the
chemoresistant group.
Another study conducted by Garofalo and colleagues,
identified a signature of miRNAs involved in TRAIL re-
sistance of human non-small cell lung cancer [77]. In par-
ticular, they performed a miRNA profiling analysis in four
NSCLC cell lines that present a different grade of re-
sistance to TRAIL treatments: CALU-1 (TRAIL-resistant),
A459 and A549 (semi-resistant) and H460 (TRAIL-
sensitive). With this analysis, they found a signature of five
significantly overexpressed miRNAs (miR-222, miR-100,
miR-221, miR-125b and miR-15b) and two downregulated
ones (miR-9 and miR-96) in resistant NSCLC cells. They
further investigated the role of miR-221 and miR-222 in
TRAIL resistance by looking at two of their target genes,
Table 2 miRNAs profiling studies correlated to drugs response
Cancer type n° of deregulated miRNAs Chemoteraupeutic drugs Reference
Breast cancer cell lines chemoresistant vs chemosensi.ve 137 (63 up, 75 down) Doxorubicine [76]
Breast cancer cell lines chemoresistant vs chemosensi.ve 15 (8 up, 7 down) Tamoxifen [61]
16 ovarian cancer cell lines 27 (18 up, 9 down) Cisplatin, doxorubicine, topotecan,
paclitaxel, docetaxel, gemtabicine
[77]
Ovarian cancer cell lines chemoresistant vs chemosensi.ve 6 (3 down in all resistant
cell lines)
Cisplatin, paclitaxel [78]
Ovarian cancer cell lines ALDH + vs ALDH-chemoresistant vs
chemosensitive ALDH + cell lines
6 up Paclitaxel [79]
Lung cancer cell lines chemoresistant vs chemosensi.ve 7 (5 up, 2 down) TRAIL [80]
Prostate cancer cell lines chemoresistant vs chemosensi.ve 10 (5 up, 5 down) Cisplatin, docetaxel [81]
Gastric cancer sapmles pre-treated vs normal 58 Cisplatin, 5-fluorouracile [82]
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Kit and p27kip1, highlighting the role of p27kip1 inhibition
as mediator of both miR-221 and miR-223 TRAIL-
resistance.
Bhatnagar and collegues performed the same study in
the context of prostate cancer by comparing miRNA
expression profiling in two prostate cancer cell lines:
WPE1-NA22 (early cancer) and WPE1-NB26 (advanced
cancer and more resistant cells) [78]. From this type of
analysis, they found five downregulated and five upregu-
lated miRNAs in WPE1-NB26 cells. They focused their
attention on the two most downregulated ones: miR-200
and miR-31, whose deregulation was also validated in
other malignant prostate cancer cell lines. Through
in vitro experiments they showed that miR-205 and
miR-31 controlled apoptosis in prostate cancer cells by
targeting antiapoptotic proteins Bcl-w and E2F6.
Kim and colleagues succeeded in identifying a miRNA
signature able to predict clinical resistance to cispaltin/
fluorouracil treatment of gastric cancer [79]. They first
compared miRNA profiles from 90 pre-treated gastric
cancer samples with miRNA expression data taken from
34 normal gastric mucosal biopsy samples obtained from
healthy donors. Subsequently, they used time to pro-
gression (TTP) as a clinical indicator for chemotherapy
response. This parameter led to identifying a signature
of 58 miRNAs. The overexpression of 30 out of 58
miRNAs was associated with delayed TTP whereas the
overexpression of the remaining 28 miRNAs was asso-
ciated with a more rapid TTP.
These types of study design, similar to the ones just
mentioned, are very innovative because they contribute
to assign to miRNAs the role of biomarkers for pre-
dicting cancer therapy outcomes, which in turn lead to
identifying in individual patients the outcome of their
cytotoxic chemotherapy.
miRNA therapeutic implications
The discovery of miRNAs adds another layer of gene
regulation that is subjected to change in human disease,
including cancer. Aberrantly expressed miRNAs play key
roles in the development of human disease, and conse-
quently the correction of these miRNA deficiencies using
antagomirs or mimic synthetic miRNA may provide a
therapeutic benefit. Indeed, miRNAs frequently acquire a
gain or a loss of function in cancer thus playing a causa-
tive role in the development of the disease [80,81]. Aber-
rant regulation of miRNAs is manifested by differential
miRNA expression in the tumor tissue compared to the
normal adjacent tissue as it has been described for in-
stance, for miR-204 in gastric cancer, miR-10b* in breast
cancer and miR-145 in mesothelioma [57,82,83]. miRNA
deregulation can be the consequence of genomic rear-
rangements or altered methylation statuses of their re-
spective promoter regions. The functional consequence of
miRNA deregulation became evident as the introduction
or repression of a single miRNA can effectively contribute
to tumorigenesis or tumor progression. Several functional
studies using cultured cancer cells and in vivo cancer
models have identified miRNAs as conventional tumor
suppressors or oncogenes. The therapeutic application of
miRNAs involves two strategies. One strategy is directed
toward a gain of function which aims to inhibit oncogenic
miRNAs by using miRNA antagonists, such as anti-miRs,
locked-nucleic acids (LNA), or antagomiRs. These miRNA
antagonists are oligonucleotides with sequences comple-
mentary to the endogenous miRNA. They carry chemical
modifications that enhance the affinity for targeting
miRNA and trapping the endogenous miRNA in a con-
figuration that is unable to be processed by RISC, or alter-
natively leads to degradation of the endogenous miRNA.
The second strategy, miRNA replacement, involves the
reintroduction of a tumor-suppressor miRNA mimic to
restore a loss of function [84]. The restoration of tumor
suppressor miRNAs might increase the efficiency of con-
ventional cancer chemotherapy. The inefficient delivery or
degradation of the miRNA requires multiple doses of re-
placement of a given tumor suppressor miRNA. Alterna-
tively, viral vectors encoding short hairpin RNAs that are
processed by the cell into mature miRNAs could be used
to transduce target cells [81,85,86]. Viral delivery of miR-
NAs can be optimized to achieve a specific and conti-
nuous level of expression. Short hairpin RNAs that are
more pre-miRNA-like or authentic pre-miRNAs them-
selves will minimize toxicity while at the same time retain
potency for their intended targets [87-89]. miRNAs pro-
vide a new opportunity because, unlike proteins, miRNA
mimics are substantially smaller, they just have to enter
the cytoplasm of target cells to be active, and can be deliv-
ered systemically using methods and technologies that are
also used for siRNAs. There are several other key obser-
vations supporting the concept of miRNA replacement
therapy. These include: (i) the majority of differentially
expressed miRNAs is suppressed in tumor tissue relative
to normal tissues, indicating that the probability for
miRNAs acting as tumor suppressors than oncogenes is
greater [90]; and (ii) inhibition of endogenous miRNA
processing induces oncogenic transformation and increa-
ses tumorigenesis, suggesting that the tumor suppressive
role of miRNAs prevails over an oncogenic role [91]. An-
other advantage of miRNA mimics is the fact that nonspe-
cific off-target effects are unlikely as miRNA mimics are
expected to behave like the natural counterpart in the
proper miRNA-mRNA interactions. The strongest ration-
ale for exploring the therapeutic potential of miRNAs,
however, is based on the observation that a single miRNA
can regulate multiple oncogenes and oncogenic pathways
that are commonly deregulated in cancer. In addition,
recent data implicating miRNAs in self-renewing tumor-
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initiating cancer cells (cancer stem cells) may significantly
extend the scope of miRNA mimics and may suggest that
miRNAs can become valuable tools in eliminating cancer
cells frequently associated with chemoresistance, metasta-
sis, and recurrence [84,92,93].
Conclusions and future prospectives
Chemoresistance still remains the greatest difficulty to
overcome in cancer therapy. The discovery of miRNAs
has opened up new opportunities in understanding the
molecular mechanisms involved in different diseases and
in developing new and more efficient therapies.
As mentioned before, miRNAs are involved in the regu-
lation of different molecular pathways and the capability
of modulating the expression of a plethora of genes makes
them master regulators of multiple networks, so that even
slight modulations in their expression levels may deter-
mine significant changes in cancer cell fate.
In this context, the research of potential prognostic
power of miRNAs is still at an early stage. Up to now,
miRNA signatures have proved to be very useful for
classifying different tumors and helpful for diagnosing
different cancer types.
As it has been extensively discussed in this review,
miRNAs, in regards to tumor cell sensitivity response to
different drug treatments, may have a positive or a nega-
tive effect, according to the type of drug, cellular context
and molecular pathway they control (Figure 2). All the
evidence gathered so far makes it possible to think of
therapy development, that include the use, alone or in
combination with anticancer drugs, of molecules that
antagonize the expression of specific miRNAs, such as
antagomirs, or that restore or strengthen the function of
miRNAs with an inhibitory effect on the expression of
pro-chemoresistance gene, such as mimics. These kinds
of molecules have still not been introduced in clinical
trials, except for one: the case of Miravirsen, that is the
first miRNA-targeted drug to enter clinical trials for the
treatment of Hepatitis C virus [94]. This drug has success-
fully reached the 2a phase of a clinical study and it con-
sists in a LNA (Locked Nucleic Acid) against miR-122, the
miRNA necessary for Hepatitis C virus replication. This
Figure 2 Schematic representation of the mechanisms of action of chemoresistance-associated miRNAs. MicroRNAs have been
demonstrated to be involved in the modulation of chemoresistance of cancer cells trough the regulation of the expression of different target
genes involved in the control of apoptosis, or multi drug resistance, or DNA repair or drug metabolism.
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study provides much promise and high hopes for success-
fully introducing miRNAs in therapies planned for dif-
ferent diseases among which certainly cancer.
It is also noteworthy to stress the opportunity sug-
gested by miRNA profiling studies in chemoresistant
models to use these molecules as predictive biomarkers
of therapy outcomes, in order to develop more effective
personalized treatments.
Thus, we can conclude that in such small molecules
great promise is hidden for the future of cancer therapy.
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